UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
09 sept. 2024 16h06 HE
|
Imunon, Inc.
September 18th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline ...
IMUNON to Host R&D Day on September 18th
28 août 2024 08h30 HE
|
Imunon, Inc.
R&D Discussion in New York City to Review IL-12’s Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts ...
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
14 août 2024 08h00 HE
|
Imunon, Inc.
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development...
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
07 août 2024 17h04 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
31 juil. 2024 08h00 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that it...
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
30 juil. 2024 08h00 HE
|
Imunon, Inc.
Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in overall survival (OS) in the intent-to-treat patient...
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
29 juil. 2024 16h05 HE
|
Imunon, Inc.
Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
24 juin 2024 08h30 HE
|
Imunon, Inc.
Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc....
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
05 juin 2024 08h30 HE
|
Imunon, Inc.
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company...
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
13 mai 2024 09h00 HE
|
Imunon, Inc.
Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 ...